Comparing scientific abstracts generated by ChatGPT to original abstracts using an artificial intelligence output detector, plagiarism detector, and blinded human reviewers

bioRxiv (Cold Spring Harbor Laboratory), Journal Year: 2022, Volume and Issue: unknown

Published: Dec. 27, 2022

Abstract Background Large language models such as ChatGPT can produce increasingly realistic text, with unknown information on the accuracy and integrity of using these in scientific writing. Methods We gathered ten research abstracts from five high impact factor medical journals (n=50) asked to generate based their titles journals. evaluated an artificial intelligence (AI) output detector, plagiarism had blinded human reviewers try distinguish whether were original or generated. Results All ChatGPT-generated written clearly but only 8% correctly followed specific journal’s formatting requirements. Most generated detected AI scores (higher meaning more likely be generated) median [interquartile range] 99.98% [12.73, 99.98] compared very low probability AI-generated 0.02% [0.02, 0.09]. The AUROC detector was 0.94. Generated scored originality (100% [100, 100] originality). a similar patient cohort size abstracts, though exact numbers fabricated. When given mixture general identified 68% being by ChatGPT, incorrectly 14% Reviewers indicated that it surprisingly difficult differentiate between two, vaguer formulaic feel Conclusion writes believable completely data. These are without any often identifiable skeptical reviewers. evaluation for conferences must adapt policy practice maintain rigorous standards; we suggest inclusion detectors editorial process clear disclosure if technologies used. boundaries ethical acceptable use large help writing remain determined.

Language: Английский

---

Child and adolescent obesity

Nature Reviews Disease Primers, Journal Year: 2023, Volume and Issue: 9(1)

Published: May 18, 2023

Language: Английский

---

GLP-1 Receptor Agonists in Non-Alcoholic Fatty Liver Disease: Current Evidence and Future Perspectives

International Journal of Molecular Sciences, Journal Year: 2023, Volume and Issue: 24(2), P. 1703 - 1703

Published: Jan. 15, 2023

To date, non-alcoholic fatty liver disease (NAFLD) is the most frequent disease, affecting up to 70% of patients with diabetes. Currently, there are no specific drugs available for its treatment. Beyond their anti-hyperglycemic effect and surprising role cardio- nephroprotection, GLP-1 receptor agonists (GLP-1 RAs) have shown a significant impact on body weight clinical, biochemical histological markers fibrosis in NAFLD. Therefore, RAs could be weapon treatment both diabetes mellitus The aim this review summarize evidence currently NAFLD hypothesize potential future scenarios.

Language: Английский

---

Emerging Role of GLP-1 Agonists in Obesity: A Comprehensive Review of Randomised Controlled Trials

International Journal of Molecular Sciences, Journal Year: 2023, Volume and Issue: 24(13), P. 10449 - 10449

Published: June 21, 2023

Obesity is a chronic disease with high prevalence and associated comorbidities, making it growing global concern. These comorbidities include type 2 diabetes, hypertension, ventilatory dysfunction, arthrosis, venous lymphatic circulation diseases, depression, others, which have negative impact on health increase morbidity mortality. GLP-1 agonists, used to treat been shown be effective in promoting weight loss preclinical clinical studies. This review summarizes numerous studies conducted the main drugs agonists class, outlining maximum achievable loss. Our aim emphasize active role outcomes of loss, as well improving hyperglycemia, insulin sensitivity, blood pressure, cardio–metabolic, renal protection. We highlight pleiotropic effects these medications, along their indications, contraindications, precautions for both diabetic non-diabetic patients, based long-term follow-up

Language: Английский

---

New insights into the treatment of obesity

Diabetes Obesity and Metabolism, Journal Year: 2023, Volume and Issue: 25(8), P. 2058 - 2072

Published: April 14, 2023

Obesity is a chronic, progressive and relapsing disease with rising global prevalence associated increased morbidity mortality reduced quality of life. Treatment obesity requires comprehensive medical approach that includes behavioural interventions, pharmacotherapy bariatric surgery. The degree weight loss all approaches highly heterogeneous, long-term maintenance remains challenging. For years, antiobesity medications have been limited in number, often delivering meagre efficacy raising numerous safety concerns. Therefore, there need for the development efficacious safe new agents. Recent insights into complex pathophysiology our understanding intervenable targets pharmacotherapies to treat improve weight-related cardiometabolic complications, namely, type 2 diabetes, hyperlipidaemia hypertension. As result, novel potent therapies emerged, such as semaglutide, glucagon-like peptide-1 receptor agonist (GLP-1RA) recently approved treatment obesity. Semaglutide 2.4 mg once weekly significantly reduces body by approximately 15%, simultaneous improvement risk factors physical functioning people Tirzepatide, first dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1RA, has demonstrated reduction exceeding 20% coupled improved measures feasible. Thus, these agents promise narrow gap between weight-loss effects behaviour previous pharmacotherapies, In this narrative review, we highlight established emerging therapeutic treatments management position them framework according their effects.

Language: Английский

---

Childhood Obesity and Cardiovascular Disease Risk

Current Atherosclerosis Reports, Journal Year: 2023, Volume and Issue: 25(7), P. 405 - 415

Published: May 31, 2023

Language: Английский

---

Medications for Obesity

JAMA, Journal Year: 2024, Volume and Issue: 332(7), P. 571 - 571

Published: Aug. 20, 2024

Obesity affects approximately 19% of women and 14% men worldwide is associated with increased morbidity. Antiobesity medications (AOMs) modify biological processes that affect appetite significantly improve outcomes, such as type 2 diabetes, hypertension, dyslipidemia.

Language: Английский

---

Gut hormone co-agonists for the treatment of obesity: from bench to bedside

Nature Metabolism, Journal Year: 2023, Volume and Issue: 5(6), P. 933 - 944

Published: June 12, 2023

Language: Английский

---

Fecal microbiota transplantation: current challenges and future landscapes

Clinical Microbiology Reviews, Journal Year: 2024, Volume and Issue: 37(2)

Published: May 8, 2024

SUMMARYGiven the importance of gut microbial homeostasis in maintaining health, there has been considerable interest developing innovative therapeutic strategies for restoring microbiota. One such approach, fecal microbiota transplantation (FMT), is main "whole microbiome replacement" strategy and integrated into clinical practice guidelines treating recurrent

Language: Английский

---

Adolescent PCOS: a postpubertal central obesity syndrome

Trends in Molecular Medicine, Journal Year: 2023, Volume and Issue: 29(5), P. 354 - 363

Published: March 22, 2023

Adolescent polycystic ovary syndrome (PCOS) is a highly prevalent, reversible, endocrine-metabolic mode essentially driven by ectopic fat, which, in turn, often results from mismatch between early adipogenesis and later lipogenesis, or prenatal postnatal weight gain. The key features of adolescent PCOS are menstrual irregularity androgen excess (hirsutism, acne, and/or high testosterone). frequently preceded rapid maturation (early variants adrenarche/pubarche puberty/menarche, also accelerated fat) diagnosed 2 8 years after menarche, thus during late adolescence adulthood. Treatment should not only focus on symptoms, but reduce the amount thereby aiming for an overall state preconception health.

Language: Английский

---